ZICCUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.04 SEK | -0.98% |
|
-4.73% | -21.15% |
| Sales 2022 | 17K 1.55K 130K | Sales 2023 | 6.32M 577K 48.15M | Capitalization | 106M 9.66M 806M |
|---|---|---|---|---|---|
| Net income 2022 | -28M -2.56M -213M | Net income 2023 | -21M -1.92M -160M | EV / Sales 2022 | 748 x |
| Net cash position 2022 | 21.52M 1.96M 164M | Net cash position 2023 | 2.14M 195K 16.29M | EV / Sales 2023 | 16.4 x |
| P/E ratio 2022 |
-1.19
x | P/E ratio 2023 |
-4.94
x | Employees | 8 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.98% | ||
| 1 week | -4.73% | ||
| Current month | -6.21% | ||
| 1 month | -6.21% | ||
| 3 months | -13.96% | ||
| 6 months | -12.97% | ||
| Current year | -21.15% |
1 week
5.66
6.60
1 month
5.506.66
Current year
5.508.26
1 year
3.349.90
3 years
1.7026.30
5 years
1.7035.40
10 years
1.7035.40
| Managers | Title | Age | Since |
|---|---|---|---|
Ann Gidner
CEO | Chief Executive Officer | 58 | 09/22/09 |
Johny Humaloja
DFI | Director of Finance/CFO | 58 | 15/23/15 |
| Chairman | 44 | 05/17/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 44 | 05/17/05 | |
Per Magnus Gerde
BRD | Director/Board Member | - | - |
| Director/Board Member | 44 | 27/21/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 6.04 | -0.98% | 8,853 |
| 26/24/26 | 6.1 | -2.56% | 6,962 |
| 25/24/25 | 6.26 | -4.28% | 13,094 |
| 24/24/24 | 6.54 | +3.81% | 21,267 |
| 23/24/23 | 6.3 | -0.63% | 1,532 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:30 pm IST
More quotes
Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.
Sector
Pharmaceuticals
Calendar
28/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -21.15% | 8.5M | |
| -3.49% | 87.17B | |
| +1.97% | 40.1B | |
| +56.59% | 25.12B | |
| -14.82% | 15.59B | |
| -8.82% | 12B | |
| -16.29% | 11.8B | |
| -41.58% | 11.8B | |
| +6.14% | 8.81B | |
| -10.88% | 8.24B |
- Stock Market
- Equities
- ZICC Stock
